|
2025
|
Invention
|
Amide substituted tricyclic guanidino compounds as prmt5 inhibitors. Provided herein are compound... |
|
|
Invention
|
Tricyclic guanidino compounds as prmt5 inhibitors. Provided herein are compounds of Formula (I) o... |
|
|
Invention
|
Triheterocyclic guanidino compounds as prmt5 inhibitors. Provided herein are compounds of Formula... |
|
|
Invention
|
Tricyclic amidino compounds as prmt5 inhibitors. Provided herein are compounds of Formula (I) or ... |
|
|
Invention
|
Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors. Provided herein are co... |
|
2024
|
Invention
|
Chemical compounds and uses thereof. Provided herein are compounds of Formula (Y) or a pharmaceut... |
|
|
Invention
|
Sulfonamino indazole compounds as inhibitors of parg. Provided herein are compounds of Formula (I... |
|
|
Invention
|
Parg inhibitor. Provided herein are crystalline forms of a PARG inhibitor having the formula of C... |
|
|
Invention
|
Combination therapy with a parg inhibitor. Provided herein is a combination of a PARG inhibitor a... |
|
|
Invention
|
Methods of treating mat2a related diseases. The present disclosure relates to use of a MAT2A inhi... |
|
|
Invention
|
Pharmaceutical compositions comprising a pkc inhibitor. Provided herein is a pharmaceutical compo... |
|
|
Invention
|
Chemical compounds and uses thereof. Disclosed herein are certain chemical compounds of Formula (... |
|
|
Invention
|
Chemical compounds and uses thereof. Disclosed herein are certain chemical compounds that inhibit... |
|
|
Invention
|
Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof. Disclosed herein ar... |
|
|
P/S
|
Pharmaceutical and biological preparations; Pharmaceutical and biological preparations for use in... |
|
|
Invention
|
Methods of treating hepatic-only metastatic uveal melanoma. Provided herein is a method of treati... |
|
|
Invention
|
Combination therapy comprising a mat2a inhibitor and a topoisomerase inhibitor, a splicing inhibi... |
|
|
Invention
|
Combination therapy comprising a parg inhibitor and a topoisomerase inhibitor for treating cancer... |
|
|
Invention
|
Heteroaryl-substituted benzimidazole compounds. Provided herein are compounds having the formula:... |
|
|
Invention
|
Heteroaryl-substituted pyrazolo/imidazo pyridine compounds. Provided herein are compounds having ... |
|
|
Invention
|
Heteroaryl-substituted imidazopyridine compounds. Provided herein are compounds having the formul... |
|
|
Invention
|
Amide and ester-substituted imidazopyridine compounds. Provided herein are compounds having the f... |
|
|
Invention
|
Treatment of er+ breast cancer comprising homologous recombination deficiency using parg inhibito... |
|
|
Invention
|
Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor. Provided herein is... |
|
2023
|
Invention
|
Cancer treatments using a prmt5 inhibitor and a mat2a inhibitor. Described herein are methods of ... |
|
|
Invention
|
Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor. Provided herein is a comb... |
|
|
Invention
|
Atropisomers of mat2a inhibitors. Disclosed herein are atropisomers of Formula (I) that are methi... |
|
|
P/S
|
Pharmaceutical and biological preparations, namely, an orally administered protein kinase C (PKC)... |
|
|
Invention
|
Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor.
Provided herein i... |
|
|
Invention
|
Methods of treating uveal melanoma with a pkc inhibitor. inter aliainter alia, ocular tumors in u... |
|
|
Invention
|
Methods of treating uveal melanoma. Provided herein is a combination therapy and methods of using... |
|
|
Invention
|
Combination therapy comprising a mat2a inhibitor and a parp inhibitor. Provided herein is a combi... |
|
|
Invention
|
Methionine adenosyltranserase 2a inhibitors.
Disclosed herein are compounds of Formula (I): or a... |
|
|
Invention
|
Methionine adenosyltransferase 2a inhibitors. Disclosed herein are compounds of Formula (I): or a... |
|
|
Invention
|
Piperazine substituted indazole compounds as inhibitors of parg. Provided herein are compounds of... |
|
|
Invention
|
Combination therapy comprising a mat2a inhibitor and an antimetabolite agent. Provided herein is ... |
|
2022
|
Invention
|
Combination therapy comprising a pkc inhibitor and a c-met inhibitor. Provided herein is a combin... |
|
|
Invention
|
2-oxoquinazoline crystalline forms. The present disclosure provides crystalline forms of the comp... |
|
|
Invention
|
Combination therapy comprising a mat2a inhibitor and a taxane.
Provided herein is a combination ... |
|
|
Invention
|
Combination therapy comprising a mat2a inhibitor and a taxane. Provided herein is a combination o... |
|
|
Invention
|
O-linked thiadiazolyl compounds as dna polymerase theta inhibitors.
Disclosed herein are certain... |
|
|
Invention
|
Combination therapy comprising a mat2a inhibitor and type i prmt inhibitor.
Provided herein is a... |
|
2021
|
Invention
|
Substituted thiadiazolyl derivatives as dna polymerase theta inhibitors.
Disclosed herein are ce... |
|
|
Invention
|
Pharmaceutical combination and tumor treatment.
A combination therapy is described involving a s... |
|
|
Invention
|
Cyclized acetamido derivatives as dna polymerase theta inhibitors.
The present invention relates... |
|
|
Invention
|
Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a... |
|
|
Invention
|
2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors.
Disclosed here... |
|
|
Invention
|
4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors.
Disclosed herein ... |
|
|
Invention
|
Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors.
Disclosed herein are ce... |
|
2017
|
P/S
|
Small molecule compounds for use in therapeutic
pharmaceuticals for the treatment of oncology. |
|
2016
|
P/S
|
Small molecule compounds for use in therapeutic pharmaceuticals for the treatment of oncology |
|
|
P/S
|
Small molecule therapeutic pharmaceuticals for the treatment of cancer |
